Upcoming Meetings

To schedule a time to meet with us at any of the upcoming events we will be attending, please click the Schedule link after the event listing.

“Next Generation”
Mobile Environmental Exposure Chambers

  • Validated mobile EECs provide consistent environmental controls in any global region reducing single center bias
  • Improved patient screening to ensure adequately symptomatic patients are enrolled
  • Gain access to the population required to meet jurisdictional agency drug or device approval

Latest News & Updates

Commencement of a Phase IIa Allergic Conjunctivitis Trial

Inflamax Research Announces Today the Commencement of a Phase IIa Allergic Conjunctivitis Trial Testing a Novel Aldehyde Trap from Aldeyra Therapeutics

Inflamax Research Inc., a full-service, global CRO, announced today that it has begun conduct of Aldeyra Therapeutics, Inc.’s (NASDAQ:ALDX) phase IIa study testing an ophthalmic solution of NS2, a novel aldehyde trap for inflammatory disease. This study will be conducted at Inflamax Research’s clinic in Toronto, Canada and involves the use of the Conjunctival Allergen Provocation Test (CAPT) as a direct allergen instillation model. This study will involve the enrollment of 100 subjects who suffer from seasonal allergic conjunctivitis and will employ the use of Inflamax’s innovative electronic diary system (ePDAT™) and electronic data capture system (QDAQ™).

Inflamax is a world leading CRO that provides unique services utilizing controlled clinical models like the well-accepted Conjunctival Allergen Provocation Test (CAPT). We are pleased to be involved in testing Aldeyra’s exciting product, whose anti-inflammatory properties mechanistically...Read Full Story

Local Entrepreneur Completes Elite Ivey Program

Inflamax Research Inc. is pleased to announce today that Dr. Anne Marie Salapatek has completed QuantumShift, a unique leadership development program and network sponsored by Ivey, KPMG Enterprise, TD, and The Globe and Mail.

Boosting entrepreneurial talent is critical for our country’s future. Successful CEOs and business leaders from across Canada have just finished an intensive program at the Ivey Business School in London, Ontario. These entrepreneurs are on the way to taking their companies to the next level.

Helping private businesses grow and improve their productivity is essential to building a more competitive Canada. Ivey Business School and KPMG Enterprise realize this and for the 12th year they invited a select group of entrepreneurs to participate in QuantumShift, a rigorous...Read Full Story

Inflamax Research to Present Data Demonstrating Validation of Environmental Exposure Chambers for Pivotal Allergy Research at the Paul-Ehrlich Institute in Germany

Dr. Anne Marie Salapatek will be discussing the validation of environmental exposure chambers (EECs) for use in pivotal clinical trials and how this clinical approach should be examined rationally for its utility in pivotal immunotherapy testing for allergies.

Inflamax Research Inc., a full-service CRO, announced today that their Chief Scientific Officer, Dr. Anne Marie Salapatek, has been invited to speak at the 14th International Paul-Ehrlich Institute Seminar on Allergen Products for Diagnosis and Therapy: Regulation and Science, held in Bad Nauheim, Germany from October 29th to November 1st, 2014. The international seminar has been an expert forum and medium for discussion for scientists and regulators for approximately 30 years. This year’s event will address industry standardization and regulatory issues related to diagnostic and therapeutic allergen products.

Dr. Salapatek will review the validation methods utilized for EEC clinical trials, including the selection of ...Read Full Story

  Inflamax Research CSO to Present Data Demonstrating the Utility of Environmental Exposure Chambers in Asthma & Allergic Rhinitis Research at ERS 2014 - Press Release

Dr. Anne Marie Salapatek, CSO at Inflamax Research, will be presenting clinical trial data demonstrating the utility of Environmental Exposure Chambers in asthma and allergic rhinitis research at upcoming 2014 European Respiratory Society conference in Munich, Germany, September 6-10.

Inflamax Research Inc., a full-service CRO, announced today that their Chief Science Officer, Dr. Anne Marie Salapatek, will be presenting clinical trial data demonstrating how Environmental Exposure Chambers (EECs) can be utilized for the development of clinical trial programs aimed at showing safety and efficacy without the need for costly, large scale field studies.

The data being presented, across three poster presentations, is a representation of study design types that demonstrates how baseline allergic rhinitis symptoms can be provoked consistently out of allergy season. Patients are treated with an investigational or already-approved product, and then provoked again post-treatment to determine...Read Full Story

  Inflamax Research’s CSO Presents High Correlation between Patient Reported Allergic Rhinoconjunctivitis Symptom Scores in an EEC and the Field for House Dust Mite Allergy - Press Release

Dr. Anne Marie Salapatek, President & Chief Scientific Officer of Inflamax Research, will be presenting results of a meta-analysis outlining statistically significant correlations between house dust mite symptoms in the traditional Field trial approach and those collected from patients in the Environmental Exposure Chamber (EEC). These findings support the use of EEC allergen challenge approach for pivotal testing.

Dr. Salapatek, an internationally renowned scientist with expertise in allergy, asthma and EEC clinical trials, is an invited speaker at the EAACI meeting. “This data shows that conducting studies in the EEC provides the best research option that reduces the variability seen in field trials whilst providing an accurate read of a therapy’s efficacy, and importantly also which well reflects that seen in the traditional field trial approach”, states Dr. Salapatek. These findings are to be presented at the 2014 The European Academy of Allergy and Clinical Immunology (EAACI) Congress in Copenhagen, Denmark on June 10th at 1:30 pm.

Dr. Salapatek will also be presenting a poster demonstrating that correlations between skin prick tests (SPT) and specific IgE levels in patients vary...Read Full Story

  Inflamax Research, Inc. Announces Fully-Integrated Clinical e-Source Data Management Services - Press Release

Released October 24, 2013

The CDM team has experience with electronic data capture services, having built, released, and “locked” 375 databases since 2006 in multiple study designs and therapeutic areas. All team members are members of the Society for Clinical Data Management (SCDM) and all have achieved their Certified Clinical Data Manager (CCDM) status.

The utilization of CDISC and CDASH standards provides the industry-standard data exchange models which facilitates submission for FDA requirements. In addition to a full complement of data management services, including web-based fully compliant 21 CFR Part 11 electronic data capture capability via secure Internet access, Inflamax Research Inc. has integrated its e-Source data capture in the clinic seamlessly into good data management practices...Read Full Story

Read All News at Inflamax Research